Author

S. Godbole

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 8 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 8 Research Focus:host-pathogen & immune response· 7 Organism:human· 6 Assay:proteomics· 5 Research Focus:drug response / drug discovery· 4 Organism:non-human primate· 3 Research Focus:benchmarking· 2 Research Focus:cell type annotation· 1

Frequent Co-Authors

A. R. Henry· 6 shared M. E. Davis-Gardner· 5 shared M. S. Suthar· 5 shared D. C. Douek· 4 shared L. Pessaint· 4 shared M. Gagne· 4 shared A. Dodson· 3 shared A. Van Ry· 3 shared

Activity by Year

2021-2024 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

6 shared papersImmunology

A. R. Henry

Mutual co-authors in cluster

Author profile →

9 papers

Recent·Most cited

XBB.1.5 monovalent booster improves antibody binding and neutralization against emerging SARS-CoV-2 Omicron variants

S. Jain, S. Kumar, L. Lai, S. Linderman, A. A. Malik, M. L. Ellis, S. Godbole, D. Solis, M. K. Sahoo, K. Bechnak, I. Paredes, R. Tanios, B. Kazzi, S. M. Dib, M. B. Litvack, , M. S. Suthar

The paper evaluates the effectiveness of an XBB.1.5 monovalent booster vaccine, showing improved antibody binding and neutralization against SARS-CoV-2 Omicron variants.

bioRxiv · Feb 3, 2024 · PreprintImmunology

Durable immunity to SARS-CoV-2 in both lower and upper airways achieved with a gorilla adenovirus (GRAd) S-2P vaccine in non-human primates

J. I. Moliva, S. F. Andrew, B. J. Flynn, D. A. Wagner, K. E. Foulds, M. Gagne, D. R. Flebbe, E. Lamb, S. Provost, J. Marquez, A. Mychalowych, C. Lorag, C. C. Honeycutt, M. R. Burnett, L. McCormick, , Nason

This study shows a gorilla adenovirus-based vaccine provides durable immunity against SARS-CoV-2 in both airways of non-human primates, with enhanced protection from aerosol delivery and prime-boost regimens.

bioRxiv · Nov 22, 2023 · PreprintImmunology

Mucosal Adenoviral-vectored Vaccine Boosting Durably Prevents XBB.1.16 Infection in Nonhuman Primates

M. Gagne, B. J. Flynn, S. F. Andrew, D. R. Flebbe, A. Mychalowych, E. Lamb, M. E. Davis-Gardner, M. R. Burnett, L. A. Serebryannyy, B. C. Lin, L. Pessaint, J.-P. M. Todd, Z. E. Ziff, E. Maule, R. Carroll, , M Suthar

This study shows that mucosal adenoviral-vectored vaccines provide durable protection against XBB.1.16 infection in nonhuman primates, outperforming intramuscular boosting in reducing virus replication in both upper and lower airways.

bioRxiv · Nov 6, 2023 · PreprintImmunology

Multiomic profiling of medulloblastoma reveals subtype-specific targetable alterations at the proteome and N-glycan level

H. L. Voss, S. Godbole, S. Schlumbohm, Y. Schumann, B. Peng, M. Mynarek, S. Rutkowski, M. Dottermusch, M. Dorostkar, A. Korshunov, T. Mair, S. Pfister, P. Neumann, C. Hartmann, J. Weiss, , J. E. Neumann

This study identifies subtype-specific proteome and N-glycan alterations in medulloblastoma that may serve as therapeutic targets.

bioRxiv · Jan 9, 2023 · PreprintCancer Biology

mRNA bivalent booster enhances neutralization against BA.2.75.2 and BQ.1.1

M. E. Davis-Gardner, L. Lai, B. Wali, H. Samaha, D. Solis, M. Lee, A. Porter-Morrison, I. T. Hentenaar, F. Yamamoto, S. Godbole, D. C. Douek, F. E.-H. Lee, N. Rouphael, A. Moreno, B. A. Pinsky, M. S. Suthar

This study evaluates the neutralizing efficacy of bivalent mRNA boosters against emerging SARS-CoV-2 subvariants BA.2.75.2 and BQ.1.1, showing improved protection compared to monovalent boosters.

bioRxiv · Oct 31, 2022 · PreprintImmunology

A multispecific antibody prevents immune escape and confers pan-SARS-CoV-2 neutralization

J. Misasi, R. R. Wei, L. Wang, A. Pegu, C.-J. Wei, O. Oloniniyi, T. Zhou, J. I. Moliva, B. Zhao, M. Choe, E. S. Yang, Y. Zhang, M. Boruszczak, M. Chen, K. Leung, , N. J. Sullivan

This paper develops multispecific antibodies that neutralize all SARS-CoV-2 variants, including Omicron, by targeting multiple epitopes on the spike protein.

bioRxiv · Jul 29, 2022 · PreprintImmunology

mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron

M. Gagne, J. I. Moliva, K. E. Foulds, S. F. Andrew, B. J. Flynn, A. P. Werner, D. A. Wagner, I.-T. Teng, B. C. Lin, C. Moore, N. Jean-Baptiste, R. Carroll, S. L. Foster, M. Patel, M. Ellis, , Naisan

This study compares B cell responses and protection against Omicron after boosting vaccinated macaques with mRNA-1273 or mRNA-Omicron vaccines, finding comparable immunity and protection.

bioRxiv · Feb 3, 2022 · PreprintImmunology

mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 Omicron variant

V.-V. Edara, K. E. Manning, M. Ellis, L. Lai, K. M. Moore, S. L. Foster, K. Floyd, M. E. Davis-Gardner, G. Mantus, L. E. Nyhoff, S. Bechnack, G. Alaaeddine, A. Naji, H. Samaha, M. Lee, , M. S. Suthar

This study evaluates the neutralizing activity of mRNA vaccines against the SARS-CoV-2 Omicron variant, showing reduced efficacy after the second dose but improved responses following a third dose.

bioRxiv · Dec 20, 2021Immunology

Durability of immune responses to the BNT162b2 mRNA vaccine

M. Suthar, P. S Arunachalam, M. Hu, N. Reis, M. Trisal, O. Raeber, S. Chinthrajah, M. E. Davis-Gardner, K. Manning, P. Mudvari, S. Godbole, E. Boritz, A. R. Henry, D. Douek, K. Nadeau, , P. Halfmann

This study shows that antibody and T cell responses to the BNT162b2 vaccine wane significantly at 6 months, suggesting a potential need for a third booster dose.

bioRxiv · Sep 30, 2021Immunology